Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis
Gabriela Mladonická Pavlasová(Central European Institute of Technology), Marek Mráz(Central European Institute of Technology), Raffaele Calogero(University of Turin), Thomas J. Kipps(University of California San Diego), Michael Doubek(Central European Institute of Technology), Jiřı́ Mayer(Masaryk University), Marek Borský(Masaryk University), Matthew S. Davids(Dana-Farber Cancer Institute), Martin Trbušek(Masaryk University), Šárka Pospı́šilová(Central European Institute of Technology), Jitka Osičková(Masaryk University), Václav Šeda(Central European Institute of Technology), Kateřina Amruz Černá(Central European Institute of Technology), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 108
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k